This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dobrzanski, M. J. Articles by Dutton, R. W. Search for Related Content PubMed PubMed Citation Articles by Dobrzanski, M. J. Articles by Dutton, R. W.

Effector Cell-Derived Lymphotoxin and Fas Ligand, but not Perforin, Promote Tc1 and Tc2 Effector Cell-Mediated Tumor Therapy in Established Pulmonary Metastases

Trudeau Institute, Saranac Lake, New York

Cytolytic CD8⁺ effector cells fall into two subpopulations based on cytokine secretion. Type 1 CD8⁺ T cells (Tc1) secrete IFN-, whereas type 2 CD8⁺ T cells (Tc2) secrete interleukin (IL)-4 and IL-5. Although both effector cell subpopulations display Fas ligand (FasL) and tumor necrosis factor (TNF), tumor lysis is predominantly perforin dependent in vitro. Using an ovalbumin-transfected B16 lung metastasis model, we show that heightened numbers of adoptively transferred ovalbumin-specific Tc1 and Tc2 cells accumulated at the tumor site by day 2 after therapy and induced tumor regression that enhanced survival in mice with pulmonary metastases. Transfer of either TNF-- or perforin-deficient Tc1 or Tc2 effector cells generated from specified gene-deficient mice showed no differences in therapeutic efficiency when compared with corresponding wild-type cells. In contrast, both Tc1 and Tc2 cells, derived from either FasL or TNF-/lymphotoxin (LT) double knockout mice, showed that therapeutic effects were dependent, in part, on effector cell-derived FasL or LT. Six days after effector cell therapy, elevated levels of activated endogenous CD8/CD44^High and CD4/CD44^High T cells localized and persisted at sites of tumor growth, whereas donor cell numbers concomitantly decreased. Both Tc1 and Tc2 effector cell subpopulations induced endogenous antitumor responses that were dependent, in part, on recipient-derived IFN- and TNF-. However, neither effector cell-mediated therapy was dependent on recipient-derived perforin, IL-4, IL-5, or nitric oxide. Collectively, tumor antigen-specific Tc1 and Tc2 effector cell-mediated therapy is initially dependent, in part, on effector cell-derived FasL or LT that may subsequently potentiate endogenous recipient-derived type 1 antitumor responses dependent on TNF- and IFN-.

This article has been cited by other articles:

				T Bongartz, F C Warren, D Mines, E L Matteson, K R Abrams, and A J Sutton Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials Ann Rheum Dis, July 1, 2009; 68(7): 1177 - 1183. [Abstract] [Full Text] [PDF]

				M. de la Luz Garcia-Hernandez, A. Gray, B. Hubby, O. J. Klinger, and W. M. Kast Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity Cancer Res., February 1, 2008; 68(3): 861 - 869. [Abstract] [Full Text] [PDF]

				D. Yang, N. ud Din, D. D. Browning, S. I. Abrams, and K. Liu Targeting Lymphotoxin {beta} Receptor with Tumor-Specific T Lymphocytes for Tumor Regression Clin. Cancer Res., September 1, 2007; 13(17): 5202 - 5210. [Abstract] [Full Text] [PDF]

				M. J. Dobrzanski, J. B. Reome, J. C. Hylind, and K. A. Rewers-Felkins CD8-Mediated Type 1 Antitumor Responses Selectively Modulate Endogenous Differentiated and Nondifferentiated T Cell Localization, Activation, and Function in Progressive Breast Cancer J. Immunol., December 1, 2006; 177(11): 8191 - 8201. [Abstract] [Full Text] [PDF]

				T. Bongartz, A. J. Sutton, M. J. Sweeting, I. Buchan, E. L. Matteson, and V. Montori Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, May 17, 2006; 295(19): 2275 - 2285. [Abstract] [Full Text] [PDF]

				K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape J. Immunol., March 15, 2006; 176(6): 3374 - 3382. [Abstract] [Full Text] [PDF]

				J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis J. Immunol., August 1, 2004; 173(3): 1738 - 1743. [Abstract] [Full Text] [PDF]